| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
BofA expects Medtronic to post over 5% second-quarter revenue growth and maintain strong momentum through 2026, driven by robus...
Orchestra BioMed's Virtue® Sirolimus AngioInfusionTM Balloon ("Virtue SAB") is the first non-coated drug-eluting ba...
Citadel founder Ken Griffin poured cold water on Wall Street's obsession with AI at JPMorgan event saying it falls short in...
Truist Securities analyst Richard Newitter maintains Medtronic (NYSE:MDT) with a Hold and raises the price target from $96 t...
Stifel analyst Rick Wise maintains Medtronic (NYSE:MDT) with a Hold and raises the price target from $90 to $105.
Medtronic announces U.S. clinical study for Hugo robotic-assisted surgery system in gynecological procedures.
Medtronic plc (NYSE:MDT) today announced the start of the Embrace Gynecology investigational device exemption (IDE) U.S. clinic...